The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program

被引：2
作者：
Silberstein, S. [1 ]
Dodick, D. W. [2 ]
DeGryse, R. E. [3 ]
Lipton, R. [4 ]
Turkel, C. C. [3 ]
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[2] Mayo Clin Arizona, Phoenix, AZ USA
[3] Allergan Pharmaceut Inc, Irvine, CA 92715 USA
[4] Albert Einstein Coll Med, Bronx, NY 10467 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2013年 / 14卷
关键词：
Migraine; Treatment Cycle; Chronic Migraine; Migraine Patient; Responder Rate;
D O I：
10.1186/1129-2377-14-S1-P200
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：1
相关论文
共 50 条
[31]   Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment [J].
Michail Vikelis ;
Andreas A. Argyriou ;
Emmanouil V. Dermitzakis ;
Konstantinos C. Spingos ;
Nikolaos Makris ;
Evangelia Kararizou .
The Journal of Headache and Pain, 2018, 19
[32]   OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation [J].
Cheng, Fan ;
Ahmed, Fayyaz .
EXPERT OPINION ON DRUG SAFETY, 2021, 20 (11) :1275-1289
[33]   P010. OnabotulinumtoxinA for treatment of chronic migraine: results after 1 year of treatment [J].
Eleonora Rossi ;
Chiara Lupi ;
Silvia Benemei ;
Pierangelo Geppetti ;
Francesco De Cesaris .
The Journal of Headache and Pain, 2015, 16
[34]   OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial [J].
Diener, H. C. ;
Dodick, D. W. ;
Aurora, S. K. ;
Turkel, C. C. ;
DeGryse, R. E. ;
Lipton, R. B. ;
Silberstein, S. D. ;
Brin, M. F. .
CEPHALALGIA, 2010, 30 (07) :804-814
[35]   Treatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and Safety [J].
Szok, Delia ;
Csati, Anett ;
Vecsei, Laszlo ;
Tajti, Janos .
TOXINS, 2015, 7 (07) :2659-2673
[36]   Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine [J].
Diener, H. -C. ;
Dodick, D. W. ;
Turkel, C. C. ;
Demos, G. ;
DeGryse, R. E. ;
Earl, N. L. ;
Brin, M. F. .
EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 (06) :851-859
[37]   OnabotulinumtoxinA Wear-off Phenomenon in the Treatment of Chronic Migraine [J].
Masters-Israilov, Alina ;
Robbins, Matthew S. .
HEADACHE, 2019, 59 (10) :1753-1761
[38]   Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine [J].
Bekir Enes Demiryurek ;
Devrimsel Harika Ertem ;
Atilla Tekin ;
Mustafa Ceylan ;
Yesim Guzey Aras ;
Belma Dogan Gungen .
Neurological Sciences, 2016, 37 :1779-1784
[39]   Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine [J].
Demiryurek, Bekir Enes ;
Ertem, Devrimsel Harika ;
Tekin, Atilla ;
Ceylan, Mustafa ;
Aras, Yesim Guzey ;
Gungen, Belma Dogan .
NEUROLOGICAL SCIENCES, 2016, 37 (11) :1779-1784
[40]   Pericranial Muscle Stiffness, Pain Thresholds, and Tenderness during a Treatment Cycle of OnabotulinumtoxinA for Chronic Migraine Prevention [J].
Dalby, Sebastian Worsaae ;
Hvedstrup, Jeppe ;
Carlsen, Louise Ninett ;
Ashina, Sait ;
Bendtsen, Lars ;
Schytz, Henrik Winther .
DIAGNOSTICS, 2024, 14 (03)
12345